Vilon: Side Effects
Known side effects, contraindications, and interactions
📌TL;DR
- •3 known side effects documented
- •1 mild, 0 moderate, 0 severe
- •3 contraindications listed
Compare side effects across multiple peptides →
Side Effects Severity Chart
Vilon has never been administered to humans in controlled clinical trials. The complete absence of human safety data means that the side effect profile is entirely unknown. No systematic adverse event monitoring has been conducted.
As a thymus-derived peptide bioregulator, vilon may theoretically affect immune cell differentiation and function. Whether this could lead to immune activation, suppression, or dysregulation in humans is unknown.
As a dipeptide of lysine and glutamic acid, vilon would release these constituent amino acids upon degradation. At typical research doses, the amino acid load would be negligible compared to dietary intake and unlikely to cause adverse effects.
⛔Contraindications
- •No formal contraindications have been established because no human clinical trials have been conducted. Individuals with autoimmune conditions should exercise particular caution given vilon's proposed immunomodulatory effects.
- •Pregnant or breastfeeding women should avoid vilon as no reproductive toxicology studies meeting Western regulatory standards have been published.
- •Individuals on immunosuppressive therapy should avoid vilon due to the theoretical risk of immune modulation interfering with their treatment.
⚠️Drug Interactions
- •No drug interactions have been characterized because no human pharmacokinetic or pharmacodynamic studies have been conducted.
- •Theoretical interaction with immunosuppressive medications (e.g., cyclosporine, tacrolimus, mycophenolate) based on vilon's proposed immunomodulatory mechanism.
- •Theoretical interaction with immunostimulatory agents or vaccines, as vilon may alter immune cell differentiation patterns.
Community-Reported Side Effects
See which side effects community members report most frequently.
Based on 15+ community reports
View community protocolsNo Human Safety Data#
Vilon has not been evaluated in clinical trials registered with Western regulatory agencies (FDA, EMA). All safety information below is theoretical or derived from limited preclinical animal studies conducted primarily by the Khavinson research group. No systematic adverse event monitoring has ever been conducted in humans receiving vilon.
Preclinical Safety Observations#
Mouse Studies#
In the only published in vivo safety data, Khavinson and Anisimov (2000) reported that chronic subcutaneous vilon administration to female CBA mice from 6 months of age:
- Produced no unfavorable effects on animal development
- Did not adversely affect reproductive (estrous) function
- Did not alter free radical processes
- Was associated with increased physical activity and endurance
These limited preclinical observations suggest tolerability in one mouse strain with one route of administration. They cannot be extrapolated to predict human safety.
Limitations of Preclinical Safety Data#
| Limitation | Significance |
|---|---|
| Single mouse strain (CBA) | Strain-specific effects may not generalize |
| Single sex (female) | Male-specific effects unknown |
| Single route (subcutaneous) | Oral safety not assessed |
| Single research group | No independent safety evaluation |
| No formal toxicology | No LD50, NOAEL, or dose-limiting toxicity established |
| No organ histopathology reported | Subclinical organ damage not assessed |
Theoretical Safety Considerations#
Immunomodulatory Risks#
Vilon's proposed mechanism involves modulation of thymic immune cell differentiation. Potential risks of uncontrolled immune modulation include:
- Autoimmune activation: Altered T-cell differentiation could theoretically promote autoimmune responses
- Immune suppression: Inappropriate immune modulation could increase susceptibility to infections
- Cytokine imbalance: Changes in immune cell subsets could alter cytokine profiles
Dipeptide Degradation#
As a simple dipeptide (275 Da), vilon is expected to be rapidly cleaved by ubiquitous dipeptidases in blood and tissues. The resulting free lysine and glutamic acid would enter normal amino acid metabolism. At any plausible dose, this amino acid load would be negligible compared to dietary protein intake.
Epigenetic Effects#
Vilon's reported effects on chromatin structure (deheterochromatinization) raise theoretical concerns about unintended gene activation. Reactivation of silenced genes could theoretically include tumor suppressor genes (beneficial) or oncogenes (harmful). No data exists on the specificity or reversibility of vilon's proposed epigenetic effects.
Contraindications#
No formal contraindications have been established. Based on the proposed mechanism, the following populations should exercise particular caution:
- Individuals with autoimmune conditions
- Pregnant or breastfeeding women
- Patients on immunosuppressive therapy
- Individuals with active malignancies (due to unknown effects on tumor biology)
Drug Interactions#
No drug interactions have been characterized. Theoretical interactions based on proposed mechanism:
| Drug Category | Theoretical Concern |
|---|---|
| Immunosuppressants | May counteract immunosuppressive therapy |
| Immunostimulants | Unpredictable additive immune effects |
| Cancer immunotherapy | May alter immune checkpoint dynamics |
| Vaccines | May affect immune response to vaccination |
Safety Monitoring Recommendations#
Given the absence of human data, any research use should include monitoring of:
- Complete blood count with differential (immune cell changes)
- Inflammatory markers (CRP, ESR)
- Liver and kidney function (general safety)
- Autoimmune markers if clinical suspicion arises
Related Reading#
Unlock full side effects analysis
Free access to detailed safety profiles and interaction guidance for all peptides.
150+ peptide profiles · 30+ comparisons · 18 research tools
Frequently Asked Questions About Vilon
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.